B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265

B of A Securities analyst Alec Stranahan has maintained a Buy rating on Revolution Medicines (NASDAQ: RVMD) and raised the price target from $225 to $265. This adjustment reflects a positive outlook on the company's performance.